11.25

0.54% -0.06

Stoke Therapeutics Inc (STOK)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$11.31

Aprire:

$11.26

Volume 24 ore:

29,930

Relative Volume:

0.06

Capitalizzazione di mercato:

$613.62M

Reddito:

$8.78M

Utile/perdita netta:

$-104.70M

Rapporto P/E:

-4.4466

EPS:

-2.53

Flusso di cassa netto:

$-82.68M

1 W Prestazione:

-19.19%

1M Prestazione:

-10.58%

6M Prestazione:

-26.72%

1 anno Prestazione:

+188.43%

Intervallo 1D:

$11.13

$11.42

Intervallo di 1 settimana:

$11.08

$13.95

Portata 52W:

$3.77

$17.58

Stoke Therapeutics Inc Stock (STOK) Company Profile

Nome

Stoke Therapeutics Inc

Settore

Healthcare (1195)

Industria

Biotechnology (683)

Telefono

781-430-8200

Indirizzo

45 WIGGINS AVENUE, BEDFORD, MA

Dipendente

110

Cinguettio

@stoketx

Prossima data di guadagno

2024-11-05

Ultimi documenti SEC

STOK's Discussions on Twitter

Confronta STOK con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
STOK	11.29	613.62M	8.78M	-104.70M	-82.68M	-2.53
VRTX	446.08	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	740.77	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	589.60	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	249.12	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.86	24.49B	3.30B	-501.07M	1.03B	11.54

Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-10-14	Ripresa	Leerink Partners	Outperform
2024-03-26	Aggiornamento	TD Cowen	Market Perform → Outperform
2023-11-20	Ripresa	JP Morgan	Neutral
2023-07-25	Downgrade	TD Cowen	Outperform → Market Perform
2023-05-01	Aggiornamento	BofA Securities	Underperform → Neutral
2023-04-26	Ripresa	Canaccord Genuity	Buy
2023-01-06	Downgrade	BofA Securities	Buy → Underperform
2022-10-24	Aggiornamento	SVB Leerink	Mkt Perform → Outperform
2022-01-31	Iniziato	Jefferies	Buy
2021-12-03	Iniziato	BofA Securities	Buy
2021-11-22	Aggiornamento	JP Morgan	Neutral → Overweight
2021-05-18	Iniziato	UBS	Neutral
2021-05-10	Aggiornamento	Wedbush	Neutral → Outperform
2021-04-26	Ripresa	Credit Suisse	Outperform
2021-02-10	Downgrade	Wedbush	Outperform → Neutral
2020-12-15	Ripresa	H.C. Wainwright	Buy
2020-12-11	Reiterato	Needham	Buy
2020-10-23	Iniziato	Cantor Fitzgerald	Overweight
2020-09-29	Ripresa	JP Morgan	Neutral
2020-09-29	Iniziato	Needham	Buy
2019-12-18	Iniziato	Wedbush	Outperform
2019-11-12	Iniziato	BTIG Research	Buy
2019-10-25	Iniziato	H.C. Wainwright	Buy
2019-07-15	Iniziato	Canaccord Genuity	Buy
2019-07-15	Iniziato	Cowen	Outperform
2019-07-15	Iniziato	Credit Suisse	Outperform
2019-07-15	Iniziato	JP Morgan	Overweight

Mostra tutto

Stoke Therapeutics Inc Borsa (STOK) Ultime notizie

Nov 20, 2024

Stoke Therapeutics (STOK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Zacks Investment Research

Nov 20, 2024

Nov 17, 2024

Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Recommendation of “Buy” by Brokerages - Defense World

Nov 17, 2024

Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives $20.83 Average PT from Analysts - MarketBeat

Nov 17, 2024

Los Angeles Capital Management LLC Grows Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat

Nov 15, 2024

Nov 14, 2024

Lynx1 Capital Management LP's Strategic Acquisition in Stoke The - GuruFocus.com

Nov 14, 2024

Nov 12, 2024

Wall Street Analysts Believe Stoke Therapeutics (STOK) Could Rally 66.84%: Here's is How to Trade - MSN

Nov 12, 2024

Nov 09, 2024

FY2024 EPS Forecast for Stoke Therapeutics Lifted by Analyst - Defense World

Nov 09, 2024

Nov 08, 2024

Earnings Update: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Reported And Analysts Are Trimming Their Forecasts - Simply Wall St

Nov 08, 2024

Wedbush Lifts Earnings Estimates for Stoke Therapeutics - MarketBeat

Nov 08, 2024

Research Analysts Offer Predictions for STOK FY2024 Earnings - MarketBeat

Nov 08, 2024

Research Analysts Set Expectations for STOK FY2024 Earnings - MarketBeat

Nov 08, 2024

Nov 06, 2024

Stoke Therapeutics (NASDAQ:STOK) Earns Buy Rating from Needham & Company LLC - MarketBeat

Nov 06, 2024

Industry Analysts Just Made A Huge Upgrade To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenue Forecasts - Simply Wall St

Nov 06, 2024

Need To Know: Analysts Are Much More Bullish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenues - Yahoo Finance

Nov 06, 2024

Stoke Therapeutics' (STOK) Buy Rating Reiterated at HC Wainwright - MarketBeat

Nov 06, 2024

Nov 05, 2024

Stoke Therapeutics Reports Q3 Results, Focuses on Phase 3 Study - TipRanks

Nov 05, 2024

Stoke Therapeutics (NASDAQ:STOK) Trading Down 4.1%Time to Sell? - MarketBeat

Nov 05, 2024

Stoke Therapeutics earnings beat by $0.07, revenue topped estimates - Investing.com Canada

Nov 05, 2024